FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

obligations may Instruction 1(b).			Filed	d pursuant to Section 16(a) of the Securities Exchange Act of 1934							hours per response:		0.5	
(-7					ection 30(h) of the Ir									
1. Name and Address of Reporting Person*  VAN NOSTRAND ROBERT L				2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ ITCI ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
VAN NOSTI	KAND KUB									Director	10% Owner			
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/27/2024							Officer (give t below)	itle Other below)	(specify	
C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET					mendment, Date of	Origina	ıl Filed	(Month/Day/	6. Indiv	Individual or Joint/Group Filing (Check Applicable Line)				
									X	Form filed by	ed by One Reporting Person			
(Street) NEW YORK	NY	Form filed by More than One Reporting Person									orting			
	111	10016		Rule	e 10b5-1(c)	Tran	sact	ion Indic	ation	•				
(City)	(State)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
		Table I - No	n-Deriva	tive S	Securities Acq	uired	, Dis	posed of,	or Bei	neficially (	Owned			
Date			2. Transact Date (Month/Day	-	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Followi	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
				Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)			
Common Stock	ommon Stock 02/27/202					M		20,000	A	\$18.56	29,611	D		
Common Stock			02/27/2	024		S		9,651	D	\$72.71(1)	19,960	D		
Common Stock 02/27/2			024		S		10,349	D	\$73.14(2)	9,611	D			
		Table II -			ecurities Acqu	,		,		•	wned			

## (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$18.56	02/27/2024		M			20,000	(3)	03/21/2024	Common Stock	20,000	\$0.00	0	D	

## **Explanation of Responses:**

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$72.0016 to \$73.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$73.0026 to \$73.42, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 3. This option was granted on March 21, 2014 and will expire on March 21, 2024. All shares underlying this option have vested.

/s/ Lawrence J. Hineline, Attorney-in-fact

02/28/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.